Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VT-101
- Development stage
- Unknown
- Lead developer
- Wanbang Biopharmaceuticals
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravesical Instillation
01
Overview
VT-101 is a recombinant oncolytic adenovirus injection solution currently under investigation for the treatment of non-muscle invasive bladder cancer (NMIBC). It is administered via intravesical instillation and is designed to evaluate its efficacy and safety in patients with NMIBC. Oncolytic viruses selectively infect and replicate within cancer cells, leading to cell lysis and the release of tumor antigens, which can subsequently stimulate an anti-tumor immune response.
- Other names
- alpha-tocopheroloxyacetic acidalpha-TEAa-TEA-Lysinealpha-TEA-Lysine
Beyond the preview
Go deeper on VT-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VT-101.